Dr. Gary Allenby, Aurelia Bioscience

The ability to measure binding affinity and drug-target residence time provides crucial information during the drug discovery process. In this short video, Dr Gary Allenby (Chief Scientific Officer at Aurelia Bioscience Ltd) talks about his experience with NanoBRET® Target Engagement (TE) Intracellular Kinase Assay. By employing this live-cell energy transfer technology and 3D micro-scaffolds, Dr. Allenby can perform quantitative analysis of intracellular kinase target engagement.